GlassScriptPhysician profile
Amy Mccarthy
NPI 1851005581
$1,034.60
in general payments reported to CMS, 2019-2025
9 companies · $64.98 in 2025
The $64.98 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $396 · 2024: $574 · 2025: $64.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $222.54 | 2023-2025 | Grafix Pl, Collagenase Santyl, Regranex |
| Viiv Healthcare Company | $221.70 | 2023-2024 | Dovato |
| Organogenesis INC. | $179.62 | 2024 | Puraply Wound Matrix |
| Paratek Pharmaceuticals, INC. | $128.79 | 2024 | Nuzyra |
| Convatec INC. | $116.07 | 2023-2024 | |
| Hydrofera LLC | $61.62 | 2023 | Hydrofera Blue |
| Gilead Sciences, INC. | $50.00 | 2023 | Epclusa |
| Urgo Medical North America, LLC | $37.40 | 2024-2025 | Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Solventum Corporation | $16.86 | 2025 | Promogran Prisma, Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.